D005047Chemicals & DrugsD02.455.426.559.847.638.960.675.250D04.615.638.960.675.250D09.408.348.275621960.939627Etoposideprns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation Resourcevivo:linkAnchorTextlink anchor textPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forURLLinkvivo:webpagewebpagerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson1.453350.0052839362research area of0.8165410.0144993176subject area for31246522Rubnitz JE, Lacayo NJ, Inaba H, Heym K, Ribeiro RC, Taub J, McNeer J, Degar B, Schiff D, Yeoh AE, Coustan-Smith E, Wang L, Triplett B, Raimondi SC, Klco J, Choi J, Pounds S, Pui CHJournal of clinical oncology : official journal of the American Society of Clinical OncologyClofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial. J Clin Oncol. 2019 08 10; 37(23):2072-2081.J Clin Oncol2019-06-27T00:00:002019Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial.32311140Christian S, Arain S, Patel P, Khan I, Calip GS, Agrawal V, Sweiss K, Griffin S, Cahill K, Konig H, Esen A, Shergill A, Odenike O, Stock W, Quigley JGAmerican journal of hematologyA multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. Am J Hematol. 2020 08; 95(8):937-943.Am J Hematol2020-05-08T00:00:002020A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia.Medicine-Hematology and Oncology33575800Mulford AJ, Wing C, Dolan ME, Wheeler HEHuman molecular geneticsGenetically regulated expression underlies cellular sensitivity to chemotherapy in diverse populations. Hum Mol Genet. 2021 04 26; 30(3-4):305-317.Hum Mol Genet2021-04-26T00:00:002021Genetically regulated expression underlies cellular sensitivity to chemotherapy in diverse populations.Marina ChiaraGarassinoMarina Chiara Garassino41.7886000000000087.598699999999994025Garassino, Marina ChiaraProfessor33285097Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroglu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L, CASPIAN investigatorsThe Lancet. OncologyDurvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021 01; 22(1):51-65.Lancet Oncol2020-12-04T00:00:002020Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.33439693Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, Garassino MC, De Castro Carpeno J, Califano R, Nishio M, Orlandi F, Alatorre-Alexander J, Leal T, Cheng Y, Lee JS, Lam S, McCleland M, Deng Y, Phan S, Horn LJournal of clinical oncology : official journal of the American Society of Clinical OncologyUpdated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021 02 20; 39(6):619-630.J Clin Oncol2021-01-13T00:00:002021Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).http://www.pgrn.org/pgx-of-chemotherapeutic-toxicities.htmlMy Lab ObjectivesMedicineUniversity of ChicagoMark J.RatainMark J. Ratain41.78927490000000-87.601250000000001401Ratain, Mark J.ProfessorEverett E.VokesEverett E. Vokes41.78927490000000-87.601250000000001920Vokes, Everett E.ProfessorRaviSalgiaRavi Salgia41.78927490000000-87.601250000000001937Salgia, RaviEmeritus/Emerita, ProfessorMary EileenDolan2mdtBK0UF8zMknJtY0fp/Cv/+94=Mary Eileen Dolan41.78927490000000-87.601250000000002594Dolan, Mary EileenProfessortrue1Emeritus/Emerita, ProfessorEmeritus/Emerita, Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessor